Sign in

You may login with either your assigned username or your e-mail address.
The password field is case sensitive. Forgotten your password?

Register

The Patient Portal is exclusively made available to IVF Australia patients, to allow them to share their experiences and support each other through their fertility treatments.

Existing patients registration

Sign in

You may login with either your assigned username or your e-mail address.
The password field is case sensitive. Forgotten your password?

Register

This section of the IVF Australia website is made exclusively available to GPs, Obstetricians and Gynaecologists.

For more information, please contact us.

Doctor registration

Advanced Embryo Selection (Array CGH)

What is PGD with Advanced Embryo Selection?

Advanced Embryo Selection (Array CGH) is a pre-implantation genetic diagnosis (PGD) technique that screens all 24 chromosomes in a developing embryo, enabling our scientists to select only embryos with a normal chromosome profile to transfer.

Recent scientific research has confirmed that this technique of selectively implanting chromosomally normal embryos significantly increases the pregnancy rate in IVF cycles.*

IVFAustralia is the only clinic in NSW carrying out PGD with 24Sure Array CGH (comparative genomic hybridization) technology for advanced embryo selection.

There is no waiting list to access Advanced Embryo Selection testing at IVFAustralia.

In Australia, IVFAustralia’s sister clinic Melbourne IVF, part of Virtus Health, pioneered earlier forms of single cell CGH analysis, and reported the world’s first baby from this technology in 2001.**

Who is Advanced Embryo Selection suitable for?

Advanced Embryo Selection is particularly suited for couples or individuals where:

  • The woman is aged 38 or older
  • There is a history of recurrent miscarriage
  • There has been repeated IVF failure, for example 5 or more embryos have been replaced without success
  • There has previously been a chromosomally abnormal pregnancy (eg Down syndrome)

What does Advanced Embryo Selection involve?

Advanced Embryo Selection, involves taking a few cells from a developing embryo for testing.

24Sure Array CGH technology amplifies the DNA from the cell’s nucleus by multiplying it thousands of times before being placed on a microarray, or DNA chip, where it is compared with normal male and female DNA.

This allows the scientists to accurately detect chromosomal errors, so only an embryo with a normal chromosome profile is selected for transfer, increasing the chance of a successful pregnancy.

While the majority of biopsies are undertaken on Day 5 embryos, we have the flexibility to undertake the biopsy on any day during embryo development depending on the patient’s individual circumstances.

PGD process to screen for chromosomal abnormalities

How much does PGD with Array CGH cost?

An IVF cycle with PGD has three components of cost:

  • The cost of the IVF cycle
  • The cost of the hospital stay
  • The cost of the PGD technology

At IVFAustralia the cost of PGD with Array CGH for Advanced Embryo Selection is $700 per embryo biopsied with a maximum fee of $3995 for 6 or more embryos from a single IVF cycle.

There is no Medicare rebate associated with PGD. However, your final costs may vary depending on your individual circumstances.

If you have any questions about the cost of preimplantation genetic diagnosis with IVF Australia please phone 18000 111 483 or email us.

Read more about the cost of IVF >

PGT for chromosomal abnormalities

PGT tests all 24 chromosomes in an embryo to enable the selection and transfer of embryos that are likely to have normal chromosomes.

Related Videos

What more information?

If you would like to know more about PGD with Advanced Embryo Selection please book an appointment with a fertility specialist or call 1800 111 483.

Find out the costs of Advanced Embryo Selection...
Learn more about chromosomal abnormalities...
Contact us about Advanced Embryo Selection...

* Molecular Cytogenetics 2012 5:24
*

* Wilton et al 2001 New Engl J Med 345: 1537-1541

Contact us today

Subscribe to eNewsletter

Back to top